Committed to successful collaboration
We have an ambitious growth strategy to become a leading player in neurology-focused specialty pharma. Partnerships are essential to our ambition, from biopharmas to promising specialty neuroscience innovators. We are poised for a period of transformational growth through new partnering and acquisition opportunities in addition to in-house R&D. Partner with us!
Transform Neuroscience with us
An essential part of our growth strategy is partnership along the entire therapeutic lifecycle. Merz Therapeutics has a decisive business development strategy targeting specialty neuroscience development and commercial opportunities.
Our immediate focus is on Phase 2, Phase 3, and marketed opportunities. We also know it is never too early to lay the foundations for future collaborations. At Merz Therapeutics, we are also interested in building early-stage relationships with pioneering innovators in specialty neurology.
Areas of priority disease focus include:
- Movement disorders such as dystonia, spasticity, blepharospasms, and ataxia
- Neurodegenerative diseases, including Parkinson’s disease, multiple sclerosis, and other neurodegenerative diseases characterized by motor dysfunction
- Rare and orphan neurology disease, including hereditary neuropathies ideally with movement disorder aspects
- Chronic pain indications, including migraine and peripheral neuropathic pain
Committed to successful collaboration
In every partnership, Merz Therapeutics is focused on cross-functional collaboration excellence with our partners. We believe partnerships require prioritized investment of people, time, and energy to thrive in today’s complex development and commercial environments. Merz Therapeutics is proud of our past partnership successes and our ongoing commitment to effective alliance management.
MEET SOME OF OUR PARTNERS
Partnering put into practice
Examples of Merz Therapeutics’ success through partnership:
Acorda Therapeutics Asset Acquisition
In 2024, Merz Therapeutics wholly acquired two established and well-respected commercial medicines from Acorda Therapeutics, strengthening our market position in Parkinson’s disease and expanding into the multiple sclerosis market. Post-acquisition, Merz Therapeutics further invested in global commercial infrastructure, patient access, global supply chain, and international distribution to best deliver these products to patients globally.
Vensica Investment and Partnership
Since 2021, Merz Therapeutics is both an investor in Vensica, an early-stage technology company, and also a license partner of Merz’s incobotulinmumtoxinA for use with Vensica’s innovative ultrasound-assisted delivery catheter to treat overactive bladder. Merz Therapeutics is pleased to be more than an investor to Vensica, and to act as strategic, long-term partners with shared expertise.
Teijin Partnership
In 2017, Merz Therapeutics and Teijin entered a strategic license and co-development agreement for the commercialization of incobotulinmumtoxinA in Japan. In 2019, Japan’s Ministry of Health, Labor and Welfare (MHLW) granted approval to market incobotulinmumtoxinA in Japan for the treatment of upper limb spasticity, and in 2021 for lower limb spasticity.
Daiichi-Sankyo Partnership
In our longest-running partnership, Merz Therapeutics licensed Merz’s memantine hydrochloride to Daiichi-Sankyo. In 2011, Daiichi-Sankyo announced the approval to market and manufacture memantine hydrochloride for the treatment of moderate to severe Alzheimer’s disease in Japan.
Conferences
Merz Therapeutics will attend these conferences in the coming months and looks forward to connecting in person.
November 3-5
BIO Europe (Vienna)
Conferences
Merz Therapeutics will attend these conferences in the coming months and looks forward to connecting in person.
November 18-20
Jefferies Healthcare (London)
Conferences
Merz Therapeutics will attend these conferences in the coming months and looks forward to connecting in person.
January 11
Sacks Neuroscience (San Francisco)
Conferences
Merz Therapeutics will attend these conferences in the coming months and looks forward to connecting in person.
January 12-15
JPM Healthcare (San Francisco)
Conferences
Merz Therapeutics will attend these conferences in the coming months and looks forward to connecting in person.
June 16-19
BIO International
in Boston
Introduce yourself
If you’re not sure whether it’s the right time to approach us, we assure you it is.
We always look forward to meeting biopharmas and other product innovators.
Partnering
"*" indicates required fields
